New Anti-HIV Drugs Receive FDA Approval

Now Live: Breaking Research From AIDS 2008: Podcasts, Interviews, Videos & More >>

HIV/AIDS Basics & Prevention

Just Diagnosed

HIV Treatment

Living With HIV

AIDS Policy & Activism

HIV Around the World

Conference Coverage

Project Inform

New Anti-HIV Drugs Receive FDA Approval

October 2003

Three anti-HIV drugs have recently been approved by the Food and Drug Administration, including one in a new class called fusion or entry inhibitor. Each adds something unique to the arsenal of therapies to treat HIV infection. The three include:

Drug Name	Trade Name	Company	Drug Class
T-20, enfuvirtide	Fuzeon	Hoffman La-Roche, Trimeris	entry inhibitor
FTC, emtricitabine	Emtriva	Gilead	nucleoside analog reverse transcriptase inhibitor
Atazanavir	Reyataz	Bristol-Myers Squibb	protease inhibitor

The following articles highlight information on each of the newly approved drugs and provide a discussion on how they fit into the arsenal of existing drugs.

T-20 (Enfuvirtide)
FTC (Emtricitabine)
Atazanavir (Reyataz)
Three New Drugs: Buying and Access
Bottom Line on the Three New Drugs

Back to the Project Inform Perspective October 2003 contents page.

This article was provided by Project Inform. It is a part of the publication Project Inform Perspective.

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.